Our results point to the existence of sub-lines of the MCF-7 breast cancer cell line where resistance to 4-hydroxytamoxifen is coupled to increased resistance to inhibitors of the mTOR pathway but increased sensitivity to a variety of cytotoxic anticancer drugs. Here, MTOR is linked to breast cancer.